ViiV Healthcare’s investigational broadly neutralising antibody - N6LS - successfully maintains viral suppression in long-acting treatment of HIV

12.03.25 16:44 Uhr

Results from the study demonstrate that N6LS effectively maintained undetectable viral load when combined with long-acting cabotegravir.Weiter zum vollständigen Artikel bei GlaxoSmithKline plc (GSK)

Quelle: EN, GlaxoSmithKline

Nachrichten zu GlaxoSmithKline PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs

Wer­bung